Skip to Main Content

Paper Details

ADXS31142 Immunotherapy ± Pembrolizumab Treatment for Metastatic Castration-Resistant Prostate Cancer: Open-Label Phase I/II KEYNOTE-046 Study.
Oncologist
11
2022
Author NameAffiliation
Lawrence FongUniversity of California san francisco
  • 1 - 1

Datasets

Release 1.2